Piper Sandler Maintains Overweight on Crescent Biopharma, Lowers Price Target to $32
Piper Sandler analyst Biren Amin maintains Crescent Biopharma (NASDAQ:CBIO) with a Overweight and lowers the price target from $35 to $32.
Last updated: 2026-11-19 08:23:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Crescent Biopharma, Inc. (CBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $12.40, with a market capitalization of $544.88M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.72 to $27.41. This page covers its latest market performance, valuation, price trends and company information.
$544.88M | |
$13.07 | |
$13.57 | |
$12.31 | |
$13.04 | |
284.70K | |
359.58K | |
-- | |
$27.41 | |
$8.72 | |
-- | |
2026-09-30 |
Crescent Biopharma, Inc. (CBIO) last closed at $12.40 as of 2026-11-19 00:04:00, down 4.87% ($0.63) from the previous close of $13.04.
During the latest regular trading session, CBIO traded between $12.31 and $13.57, with a volume of 284.70K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Crescent Biopharma, Inc. (CBIO) moved from $13.92 to $12.40, representing a decline of 10.95% ($1.52).
The stock traded between $12.28 and $15.44 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 270.21 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 19.7%
CBIO is currently trading at $12.40, placing it 19.7% of the way from its 52-week low of $8.72 to its 52-week high of $27.41. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 44 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Crescent Biopharma, Inc. and CBIO stock.
Piper Sandler analyst Biren Amin maintains Crescent Biopharma (NASDAQ:CBIO) with a Overweight and lowers the price target from $35 to $32.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and raises the price target from $36 to $40.
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.72) by 25 percent. This is a 29.13 percent increase over losses of $(1.27) per share
Eligible investors can buy real shares of Crescent Biopharma, Inc. (CBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CBIO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CBIO shares and USD.
CBIO Shares to USD
1.00 CBIO shares = 12.396 USD
Calculations are estimates based on the latest available price and are for reference only.